John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at Follow @JohnCFierce on Twitter.

Articles by John Carroll

UPDATED: Amgen gets a big win with FDA OK for PCSK9 cholesterol drug Repatha

Amgen scored the big win for its PCSK9 drug Repatha (evolocumab). The FDA announced Thursday afternoon that it has given Amgen a green light on marketing the PCSK9 cholesterol drug, opening the door to what will likely prove a blockbuster market.

Struggling GSK inks a translational deal with QB3

San Francisco incubator QB3 is linking up with pharma giant GlaxoSmithKline on some translational work, looking to push a few academic research projects toward the clinic.

Syndax adds Genentech PD-L1 'atezo' combo pact to its growing pipeline

Genentech has agreed to lend its closely-watched checkpoint inhibitor atezolizumab to Syndax for a combo study with the Waltham, MA-based biotech's lead drug entinostat for triple-negative breast cancer, just three days after Syndax landed an $80 million crossover round.

Repatha OK looming, analysts wait to see if Amgen will start PCSK9 price war

Amgen is likely to start today off with a case of bubbly chilling in the company cafeteria. The FDA has reached its deadline on a marketing decision for the cholesterol drug Repatha (evolocumab), which most likely is on the verge of becoming a major rival to the newly approved Praluent (alirocumab), from Regeneron and Sanofi.

J&J positions blockbuster contender daratumumab for a multiple myeloma showdown

Johnson & Johnson and Genmab have played another card in their deck of data on the multiple myeloma blockbuster contender daratumumab, spelling out some encouraging data that's now being used to help persuade the FDA to deliver a fast marketing approval.

UPDATED: Verastem shares crater on Twitter chatter around cancer data

Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response rate for KRAS mutant non-small cell lung cancer.

Pharma giants line up behind an $83M crossover round for IPO-bound Merus

Four months after signaling its interest in filing for a $100M-plus IPO on Nasdaq, Dutch biotech Merus has weighed in with an $83 million round that includes contributions from some familiar crossover investors. And the biotech may soon offer a test case on just how the biotech IPO market will function in the wake of the dizzying ride investors have been on in recent days.

Immatics, MD Anderson partner on a $60M immuno-oncology T-cell spinout

Harpreet Singh, the CSO and co-founder of Germany's Immatics Biotechnologies, has been splitting his time between Germany and Houston in order to set up a new biotech company that will collaborate with some top researchers at MD Anderson on overcoming some of the limitations to the adoptive T cell therapies now in the immuno-oncology pipeline.

Booming Regeneron snaps up more office/lab space in fast-growing campus

Boosted by a major new drug approval, a booming Regeneron Pharmaceuticals is swelling rapidly in size. The big biotech has added 116,200 square feet of office/lab space to its lease at the Landmark at Eastview research campus in Tarrytown, NY, about 30 minutes from Manhattan. The expansion swells Regeneron's footprint on the campus to a giant-sized 1.1 million square feet, according to landlord BioMed Realty Trust.

FluGen raises $12M round for universal flu vaccine

Madison, WI-based FluGen has raised a $12 million Series A from Venture Investors LLC, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board as well as existing investors led by Knox LLC. The money will fund the first human studies of REDEE FLU, a universal flu vaccine candidate.